Telehealth effectiveness for pre-exposure prophylaxis delivery in Brazilian public services: the Combine! Study
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
JOHN WILEY & SONS LTD
Autores
ESTEVAM, Denize Lotufo
MUNHOZ, Rosemeire
ARRUDA, Erico
MORAES, Renata Amaral de
WINKLER, Lisiane de Quadros
NEVES, Lis Aparecida de Souza
SANTOS, Juliane Cardoso Villela
KRUPPA, Mariele
Citação
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, v.26, n.9, article ID e26173, 12p, 2023
Resumo
IntroductionPre-exposure prophylaxis (PrEP) delivery based on user needs can enhance PrEP access and impact. We examined whether telehealth for daily oral PrEP delivery could change the indicators of care related to prophylactic use in five Brazilian public HIV clinics (testing centres, outpatient clinics and infectious disease hospitals).MethodsBetween July 2019 and December 2020, clients on PrEP for at least 6 months could transition to telehealth or stay with in-person follow-up. Clients were clinically monitored until June 2021. A desktop or mobile application was developed, comprising three asynchronous consultations and one annual in-person consultation visit. Predictors influencing telehealth preference and care outcomes were examined. The analysis encompassed intent-to-treat (first choice) and adjustments for sexual practices, schooling, age, duration of PrEP use and PrEP status during the choice period.ResultsOf 470 users, 52% chose telehealth, with the adjusted odds ratio (aOR) increasing over time for PrEP use (aOR for 25-months of use: 4.90; 95% CI: 1.32-18.25), having discontinued PrEP at the time of the choice (aOR: 2.91; 95% CI: 1.40-6.06) and having health insurance (aOR: 1.91; 95% CI: 1.24-2.94) and decreasing for those who reported higher-risk behaviour (aOR for unprotected anal sex: 0.51; 95% CI: 0.29-0.88). After an average follow-up period of 1.6 years (95% CI: 1.5-1.7), the risk of discontinuing PrEP (not having the medication for more than 90 days) was 34% lower with telehealth (adjusted hazard ratio: 0.66; 95% CI: 0.45-0.97). When adjusted by mixed linear regression, no differences in adherence (measured by mean medication possession rate) were found between in-person and telehealth (p = 0.486) or at pre- and post-telehealth follow-ups (p = 0.245). Sexually transmitted infections increased between the pre-follow-up and post-follow-up choices and were not associated with in-person or telehealth (p = 0.528). No HIV infections were observed.ConclusionsOur findings indicate that telehealth for PrEP delivery can enhance service rationalization and reinforce the prevention cascade. This approach reduces prophylaxis interruptions and is mainly preferred by individuals with lower demands for healthcare services.
Palavras-chave
Brazil, effectiveness, human immunodeficiency virus, pre-exposure prophylaxis, prevention, telehealth
Referências
- Bärnighausen K, 2021, CULT HEALTH SEX, V23, P1198, DOI 10.1080/13691058.2020.1770333
- Chasco EE, 2021, AM J PREV MED, V61, pS108, DOI 10.1016/j.amepre.2021.05.040
- Chasco EE, 2021, AIDS BEHAV, V25, P2463, DOI 10.1007/s10461-021-03209-9
- Coy KC, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25252
- Grangeiro A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009021
- Gregson S, 2021, LANCET HIV, V8, pe251, DOI 10.1016/S2352-3018(21)00068-0
- Grulich AE, 2018, LANCET HIV, V5, pE629, DOI 10.1016/S2352-3018(18)30215-7
- Guaraldi G, 2021, CLIN INFECT DIS, V73, pE1222, DOI 10.1093/cid/ciaa1864
- Hoagland B, 2021, BRAZ J INFECT DIS, V25, DOI 10.1016/j.bjid.2020.11.002
- Hoth AB, 2019, SEX TRANSM DIS, V46, P507, DOI 10.1097/OLQ.0000000000001017
- Hughes SD, 2021, J MED INTERNET RES, V23, DOI 10.2196/22650
- John SA, 2020, JAIDS-J ACQ IMM DEF, V85, P302, DOI 10.1097/QAI.0000000000002459
- Koester KA, 2020, J INT ASSOC PRO AIDS, V19, DOI 10.1177/2325958220919269
- Koss CA, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003492
- Mayer CM, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25276
- Ogunbajo A, 2021, AIDS BEHAV, V25, P2301, DOI 10.1007/s10461-021-03159-2
- Pitasi MA, 2021, MMWR-MORBID MORTAL W, V70, P1669, DOI 10.15585/mmwr.mm7048e1
- Player MS, 2022, AIDS CARE, V34, P1499, DOI 10.1080/09540121.2021.2018567
- Refugio ON, 2019, JAIDS-J ACQ IMM DEF, V80, P40, DOI 10.1097/QAI.0000000000001873
- Rousseau E, 2021, CURR HIV-AIDS REP, V18, P500, DOI 10.1007/s11904-021-00578-7
- Rusie LK, 2018, CLIN INFECT DIS, V67, P283, DOI 10.1093/cid/ciy160
- Siegler AJ, 2019, CLIN INFECT DIS, V68, P501, DOI 10.1093/cid/ciy529
- Smith DK, 2020, CLIN INFECT DIS, V71, P3144, DOI 10.1093/cid/ciz1229
- Stekler JD, 2018, JAIDS-J ACQ IMM DEF, V77, pE40, DOI 10.1097/QAI.0000000000001621
- Tassi MF, 2021, J ANTIMICROB CHEMOTH, V76, P3002, DOI 10.1093/jac/dkab263
- Touger R, 2019, CURR HIV-AIDS REP, V16, P113, DOI 10.1007/s11904-019-00430-z
- Vanhamel J, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05568-w
- Wong KYK, 2020, MHEALTH, V6, DOI 10.21037/mhealth.2019.12.06